IDO1 and neoplasm: A crucial consequence of immune activation is the release of interferon‐gamma into the tumor microenvironment, which subsequently potentiates immune responses (e.g., by enhancing APM expression) and triggers adaptive immunosuppressive mechanisms (e.g., by inducing expression of checkpoint proteins such as PD‐L1/2, TIGIT and IDO1) [30].